Biotech failure, 2002 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (66)	5/19/2002 10:55:12 PM
From: Miljenko Zuanic	Read Replies (1) of 130

Failure is for H&N cancer (PII and PIII), where companies (IMCL and B-k-S) where hopping to get approvable data. This is now history (C225 + radiation may fire better, but will not be sufficient for approval). 10% response for C225 monotherapy in ref-CC is good, but again trial is too small and time to disease progression or survival benefit are hidden from press. I think that Oxaliplatin will substitute Irino (in EU already did), and Xeloda will substitute FU as first (and second) line advance CC combination therapy. It means that C225 safety will need to be tested with this drug as well. One more thing, C225 safety profile is still open for debate. <<The most common adverse events reported during the study using the combination of cetuximab and irinotecan, fluorouracil and leucovorin were neutropenia (occurring in 59 percent of patients), an acne-like rash (occurring in 76 percent of patients), nausea (occurring in 69 percent of patients), diarrhea (occurring in 69 percent of patients), and mucositis (occurring in 59 percent of patients).>> Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next